The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia

被引：0

作者：

Erdmann, R. ^{[1
,2
]}

Jorgensen, H. ^{[3
]}

Ben-Batalla, I. ^{[1
,2
]}

Kruse, N. ^{[1
,2
]}

Micklem, D. ^{[4
]}

von Amsberg, G. ^{[1
]}

Schafhausen, P. ^{[1
]}

Schultze, A. ^{[1
]}

Wroblewski, M. ^{[1
,2
]}

Binder, M. ^{[1
]}

Cubas-Cordova, M. ^{[1
,2
]}

Hadlich, T. ^{[1
]}

Janing, M. ^{[1
,2
]}

Sawall, S. ^{[1
,2
]}

Witzke, V. ^{[1
,2
]}

Lorens, J. ^{[4
]}

Allan, E. ^{[3
]}

Mukherjee, L. ^{[3
]}

Morrison, H. ^{[3
]}

Cassells, J. ^{[3
]}

Koerger, N. ^{[5
]}

Lorens, J. B. ^{[6
]}

Clark, R. ^{[7
]}

Koschmieder, S. ^{[8
]}

Vandenberghe, P. ^{[9
]}

Bruemmendorf, T. ^{[8
]}

Hochhaus, A. ^{[10
]}

Carmeliet, P. ^{[11
]}

Holyoake, T. ^{[3
]}

Pantel, K. ^{[2
]}

Bokemeyer, C. ^{[1
,12
]}

Loges, S. ^{[1
,2
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Med Clin 2, Hamburg, Germany

[2] Dept Tumor Biol, Hamburg, Germany

[3] Univ Glasgow, Paul OGorman Leukemia Res Ctr, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland

[4] BerGenBio AS, Jonas Lies, Bergen, Norway

[5] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Bone Marrow Transplantat Unit, Hamburg, Germany

[6] Univ Bergen, Dept Biomed, Bergen, Norway

[7] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England

[8] Univ Klinikum RWTH Aachen, Aachen, Germany

[9] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium

[10] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[11] VIB, Lab Angiogenesis & Neurovasc Link, Vesalius Res Ctr, Leuven, Belgium

[12] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol & Oncol, Hamburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V935

引用

页码：309 / 309

页数：1

共 50 条

[31] Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies
Tauchi, Tetsuzo
Katagiri, Seiichiro
Okabe, Seiichi
Ashihara, Eishi
Kimura, Shinya
Maekawa, Taira
Ohyashiki, Kazuma
BLOOD, 2011, 118 (21) : 1063 - 1064
[32] MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML).
Giles, Francis
Cortes, Jorge
Bergstrom, Donald A.
Xiao, Alan
Bristow, Penny
Jones, Dan
Verstovsek, Srdan
Thomas, Deborah
Kantarjian, Hagop
Freedman, Steven J.
BLOOD, 2006, 108 (11) : 52A - 52A
[33] A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib
Cea, Michele
Cirmena, Gabriella
Garuti, Anna
Rocco, Ilaria
Palermo, Claudia
Cagnetta, Antonia
Moran, Eva
Colombo, Nicoletta
Grasso, Raffaella
Fugazza, Giuseppina
Gobbi, Marco
Nencioni, Alessio
Ballestrero, Alberto
Patrone, Franco
LEUKEMIA RESEARCH, 2010, 34 (09) : E240 - E242
[34] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Giles, Francis J.
Cortes, Jorge
Jones, Dan
Bergstrom, Donald
Kantarjian, Hagop
Freedman, Steven J.
BLOOD, 2007, 109 (02) : 500 - 502
[35] The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge
Nicolini, Franck E.
Chomel, Jean-Claude
Roy, Lydia
Legros, Laurence
Chabane, Kaddour
Ducastelle, Sophie
Nicolas-Virelizier, Emmanuelle
Michallet, Mauricette
Tigaud, Isabelle
Magaud, Jean-Pierre
Turhan, Ali
Guilhot, Francois
Hayette, Sandrine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (05): : 394 - 399
[36] PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation
Yang, Ke
Fu, Kai
Zhang, Hong
Wang, Xiaokun
To, Kenneth K. W.
Yang, Caibo
Wang, Fang
Chen, Zhe-Sheng
Fu, Liwu
MOLECULAR CANCER, 2024, 23 (01)
[37] Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
Zhang, Hao
Hu, Yongxian
Chang, Alex H.
Huang, He
REGENERATIVE THERAPY, 2020, 14 : 40 - 42
[38] PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL
Paquette, Ronald L.
Shah, Neil P.
Sawyers, Charles L.
Martinelli, Giovanni
John, Nicoll
Chalukya, Meenal
Rocchetti, Maurizio
Fiocchi, Carina
Clomis, Sylvia
Capolongo, Laura.
Laffranchi, Bernard
BLOOD, 2007, 110 (11) : 312A - 312A
[39] The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Eide, Christopher A.
Adrian, Lauren T.
Tyner, Jeffrey W.
Mac Partlin, Mary
Anderson, David J.
Wise, Scott C.
Smith, Bryan D.
Petillo, Peter A.
Flynn, Daniel L.
Deininger, Michael W. N.
O'Hare, Thomas
Druker, Brian J.
CANCER RESEARCH, 2011, 71 (09) : 3189 - 3195
[40] Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Gontarewicz, Artur
Balabanov, Stefan
Keller, Gunhild
Colombo, Riccardo
Graziano, Alessio
Pesenti, Enrico
Benten, Daniel
Bokemeyer, Carsten
Fiedler, Walter
Moll, Juergen
Bruemmendorf, Tim H.
BLOOD, 2008, 111 (08) : 4355 - 4364

← 1 2 3 4 5 →